Please use this identifier to cite or link to this item:
Title: New clinical trials regulation in Spain: analysis of royal decree 1090/2015.
Authors: Martin Jimenez, M
Calvo Ferrandiz, A
Aparicio Urtasun, J
Garcia-Campelo, R
Gonzalez-Flores, E
Lazaro Quintela, M
Muñoz Mateu, M
Rodriguez Sanchez, C A
Santaballa Bertran, A
Sepulveda Sanchez, J M
Vera Garcia, R
Virizuela Echaburu, J A
Segui Palmer, M A
Keywords: Clinical trials;Low-intervention clinical trials;Non-commercial trials;Regulation 536/2014;Royal Decree 1090/2015;Transparency
metadata.dc.subject.mesh: Clinical Trials as Topic
Government Regulation
Issue Date: 7-Oct-2016
Abstract: The coming into force of Directive 2001/20/EC represented a step forward in harmonising clinical trial regulation in European countries, guaranteeing a uniform protection of subjects participating in clinical research across Europe. However, it led to a disproportionate increase in the bureaucratization, and thus, it became evident that procedures needed to be simplified without detriment to patient's safety. Thus, Regulation 536/2014, that repealed Directive 2001/20/EC, with the aim of decreasing the growing bureaucratization and stimulating clinical research in Europe, established simplified procedures, such as regulating a common procedure for authorising trials in Europe, the institution of strict assessment timelines, or the definition of new concepts, such as "low-intervention clinical trial". The legal form of a Regulation allowed the norm to be directly applied to Member States without the need for transposition. By means of the new Royal Decree, the national legislation is adapted to make the application of the regulation feasible and it allows the development of the aspects that the Regulation leaves to national legislation. Both documents seek to stimulate clinical research with medicinal products to foster knowledge, facilitate transparency, and reinforce subjects' safety. This will surely be the case, but with this revision, we will look at the novelties and key aspects that are most relevant to investigators and we will analyse the consequences for all parties involved in clinical research.
metadata.dc.identifier.doi: 10.1007/s12094-016-1550-9
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC5306195.pdf456,77 kBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons